"CD11a Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alpha-integrin subunit found on lymphocytes, granulocytes, macrophages and monocytes. It combines with the integrin beta2 subunit (CD18 ANTIGEN) to form LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1.
| Descriptor ID |
D040881
|
| MeSH Number(s) |
D12.776.395.550.200.074.500 D12.776.543.550.200.093.500 D12.776.543.750.705.408.100.100 D23.050.301.350.074.024
|
| Concept/Terms |
CD11a Antigen- CD11a Antigen
- Antigen, CD11a
- Integrin alphaL
- alphaL, Integrin
- CD11a Antigens
- Antigens, CD11a
|
Below are MeSH descriptors whose meaning is more general than "CD11a Antigen".
Below are MeSH descriptors whose meaning is more specific than "CD11a Antigen".
This graph shows the total number of publications written about "CD11a Antigen" by people in this website by year, and whether "CD11a Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD11a Antigen" by people in Profiles.
-
a7 helix region of aI domain is crucial for integrin binding to endoplasmic reticulum chaperone gp96: a potential therapeutic target for cancer metastasis. J Biol Chem. 2013 Jun 21; 288(25):18243-8.
-
A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007 Jul; 7(7):1770-7.